Suven allots shares on warrant conversion, sets up Singapore subsidiary

Warrants ConvertedFund Raising View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹317.50

prior close

₹321.75

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.0%+2.2% vs market

Healthcare Research Analytics & Technology peers, median of 5sector+0.0%+0.2% vs sector

On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.1

15m

+0.9

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-2.0+2.2+0.0+0.2

Next day

+10.2-0.1+10.4+1.0+9.2

+12.3+1.2+11.0+2.6+9.7

+13.1+1.4+11.7+0.5+12.6

+9.9+0.4+9.6-0.1+10.0

+12.5+1.0+11.5+1.6+10.9

+2.2-0.5+2.7-1.1+3.3

15d

-1.5-0.6-0.9-2.0+0.6

+5.2+3.4+1.8-2.0+7.2

+16.5+6.0+10.5+13.4+3.1

-9.5+1.1-10.6+0.2-9.7

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences board approved conversion of 1,85,70,133 warrants into equity shares at Rs 134 each to 17 non-promoter allottees, raising Rs 248.84 crore. Paid-up capital rose to Rs 28.26 crore. Board re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years and approved Suven Neurosciences Pte. Ltd., a wholly owned subsidiary in Singapore, with USD 100 million investment focused on neurological disorder treatments.

Likely market impact

Equity dilution from warrant conversion. Singapore WOS signals overseas push into neurological therapeutics with USD 100 million commitment.